{
    "id": 22401,
    "fullName": "ABL1 T277I",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 T277I lies within the protein kinase domain of the Abl1 protein (UniProt.org). T277I has been identified in sequencing studies (PMID: 26164066, PMID: 26603839), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 7776,
                    "pubMedId": 26164066,
                    "title": "Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26164066"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "T277I",
    "createDate": "05/10/2016",
    "updateDate": "11/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 119227,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130872136C>T",
        "cDna": "c.830C>T",
        "protein": "p.T277I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6376,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Iclusig (ponatinib) resulted in a major molecular response in a patient with heavily pretreated chronic myeloid leukemia expressing BCR-ABL1, ABL1 F359I, and T277I in a minority of BCR-ABL1 positive clones (PMID: 26603839).",
            "molecularProfile": {
                "id": 22978,
                "profileName": "BCR - ABL1 ABL1 T277I ABL1 F359I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7992,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359I (84%), F359I/T277I (2%), G250E (1%), and E507G (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26130,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T277I ABL1 F359I ABL1 E507G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22978,
            "profileName": "BCR - ABL1 ABL1 T277I ABL1 F359I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26130,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 T277I ABL1 F359I ABL1 E507G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119227,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130872136C>T",
            "cDna": "c.830C>T",
            "protein": "p.T277I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}